TMCnet News
Estar Medical Wins Patent Infringement Lawsuit Against RegenlabHOLON, Israel, June 19, 2018 /PRNewswire/ -- The Regional Dusseldorf District Court entirely dismissed the Regenlab infringement claim against Estar Medical, concludes no infringement of patents Estar Technologies Ltd. (Estar Medical), a leading global developer and manufacturer of innovative medical technologies in the biologics, regenerative medicine and platelet rich plasma (PRP) fields, today announced that on June 5, 2018, the Dusseldorf Regional Court ruled in favor of Estar Medical in the patent infringement lawsuit initiated by Regenlab SA. "We are pleased that the Dusseldorf Court ruled in Estar Medical's favor, agreeing that Estar did not infringe the Regenlab patent. Estar Medical has remained confident in its non-infringement positions since the case was first filed in 2016. It is gratifying to see that confidence affirmed," said Aaron Esteron, CEO at Estar Medical. "We believe that this win further validates our leadership position in the PRP and Cell Therapy market." Unless the Opposition Division of the EPO changes its views at an oral hearing, the result will be the complete invalidation and revocation of the Turzi PRP patent in all contracting states of the European Patent Convention. About Estar Technologies Ltd. For more information about Estar Medical or its PRP and Cell Therapy technology and products, please visit http://www.estar-medical.com.
SOURCE Estar Technologies Ltd. (Estar Medical) |